CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 100 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02694536
NCT02694536Phase 3Completed
CompareCT.gov

A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Hoffmann-La Roche·interventional·Posted Feb 29, 2016·Updated Mar 24, 2017

In Brief

A Phase 3 clinical trial evaluating Erlotinib and Gemcitabine for Pancreatic Cancer. Completed, enrolled 80 participants across 11 sites.

Detailed Summary

This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesItaly
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 29, 2016
Enrollment StartAug 1, 2006
Primary CompletionNov 19, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.3 years ago

Interventions

Erlotinibdrug

Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.

Gemcitabinedrug

Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.